Literature DB >> 26759579

A systematic review and meta-analysis on controlled treatment trials of metacognitive therapy for anxiety disorders.

Ramin Sadeghi1, Naghmeh Mokhber2, Leili Zarif Mahmoudi1, Negar Asgharipour2, Hamid Seyfi2.   

Abstract

BACKGROUND: To conduct a systematic review and meta-analysis on controlled treatment trials of meta-cognitive therapy for anxiety disorders.
MATERIALS AND METHODS: Studies were included if they employed controlled methodology and treated people above 18 years with anxiety disorders. Case studies (with less than 4 cases) and single case designed studies were excluded. A comprehensive literature search identified 15 trials for systematic review.
RESULTS: All included studies showed better treatment results in the MCT arms compared to the control groups. We also statistically pooled the results across studies (when possible). The meta-analyses also showed that MCT had statistically significant better results compared to the control groups in GAD (both immediately post-treatment and 12 months post-therapy results), OCD, and PTSD (p-values ranged <0.0001-0.025).
CONCLUSION: Based on the results of our systematic review, MCT seems to be an effective treatment for anxiety disorders and can effectively control their psychological problems.

Entities:  

Keywords:  Anxiety disorders; meta-analysis; meta-cognitive therapy

Year:  2015        PMID: 26759579      PMCID: PMC4696377          DOI: 10.4103/1735-1995.170632

Source DB:  PubMed          Journal:  J Res Med Sci        ISSN: 1735-1995            Impact factor:   1.852


INTRODUCTION

The two most prevalent mental health problems in the general medical setting are anxiety and depression. These two disorders are prevalent, disabling, and often untreated in primary care and have a huge burden on health economy.[1] According to USA National Comorbidity Survey Replication, anxiety disorders are the most prevalent class (28.8%) among mood, impulse-control, and substance use disorders. Among anxiety disorders, the more prevalent 12-month disorders were specific phobia (8.7%) and social phobia (6.8%).[2] Anxiety disorders impose a high burden and in comparison with other psychiatric disorders cause more uncertainty feeling and fear for patients. Unlike social anxiety disorder that is caused by a special event (such as speaking in public or a first date), generalized anxiety disorders (GAD) last at least 6 months and can get worse if left untreated.[34] Some new therapies for anxiety disorders are available, that can help some patients with anxiety disorders to lead productive, more joyful lives. Although cognitive and behavioral therapies (CBT) have produced large effect sizes (ES) for individually delivered treatments (van Balkom et al.), one of the major challenges in these therapies is to make effective treatments more readily available for the patients.[56] The aim of CBT is changing maladaptive beliefs and behaviors. Although CBT can have beneficial effects on many patients, their therapeutic effect is still under question.[7] For the first time, Wells and Matthews presented a metacognitive model for treatment of emotional disorders. The term metacognition refers to any kind of cognitive process that provided cognitive evaluation or control.[8] Metacognition has a main role in forming and developing anxiety disorders. This is the reason that metacognitive therapy (MCT) has emerged to address deficiency in CBT. Self-regulatory executive function model is the way to understand how cognition and behavior interaction works in the maintenance of anxiety disorders. Based on this perspective, metacognitive beliefs and emotional disorders have positive relationship.[910] Metacognitive model of anxiety disorders tries to adjust erroneous negative metacognitive beliefs, positive metacognitive beliefs, and the unhelpful thought-control strategies. In this method, patients should learn new ways of relating to inner thoughts that act as triggers for worrying. In addition, MCT modifies the meaning and consequences of intrusive thoughts and feelings, and beliefs about the necessity of doing rituals.[11] In case of posttraumatic stress disorder (PTSD), this type of therapy helps patients to develop flexible metacognitive awareness and control, and also to free themselves from worry/rumination, and threat monitoring.[12] Several studies showed the effectiveness of MCT on all types of anxiety disorders thus far,[12131415] however, no comprehensive literature review exists in this regard. In this study, we conducted a comprehensive literature search on the efficacy of MCT on anxiety disorders and provided the results in a systematic review and meta-analysis format.

METHODS

The PRISMA statement was followed for the conduction of the current systematic review (www.prisma-statement.org).

Search strategy

The following databases were searched for the possible relevant studies: PubMed, Scopus, Scholar Google, Cochrane database, and Psycinfo. “(Meta-cognition OR metacognitive) AND (anxiety OR Generalized Anxiety Disorder (GAD) OR Obsessive-Compulsive Disorder (OCD) OR Post Traumatic Stress Disorder (PTSD) OR phobia)” were used as keywords to search the above-mentioned databases. No language or date limit was imposed on the search. Two authors conducted the search independently.

Inclusion criteria

All studies used metacognitive treatment for anxiety disorders with the following criteria were included: Participants should be above 18 and have met full criteria for any of anxiety disorders including GAD, OCD, PTSD, specific and social phobia, and panic disorder. Only controlled studies (i.e., studies with a control group) were included: Case studies (with <4 cases) and single case designed studies were excluded. Study selection was done by two authors independently. Duplicate studies were discussed, and only the most recent reports were included. References of the included studies were hand searched in order not to miss any possible relevant study.

Statistical analyses

Studies with enough quantitative data were further analyzed by meta-analysis. At least sample size, pre- and post-therapy means, and standard deviations for psychological tests scores in MCT and control arms were needed for meta-analysis. Means and standard deviations of difference in pre- and post-treatment scores were calculated according to Cochrane Collaboration guidelines for quantitative data processing. The calculated ES for each study was standardized difference in means of pre- and post-treatment psychological test score changes (MCT compared to the control arms). Random effects model was used to pool the ES across the included studies.[16] Cochrane Q value was used to evaluate the heterogeneity across studies, and P < 0.05 were considered statistically significant. I2 index was used to quantify the amount of heterogeneity. All statistical analyses were performed using comprehensive meta-analysis version 2.

RESULTS

PRISMA flowchart of the study is shown in Figure 1. As shown in Figure studies finally met our inclusion criteria.
Figure 1

PRISMA flowchart of the study

PRISMA flowchart of the study Table 1 shows the characteristics of the included studies. Tables 2 and 3 shows the quality assessment of the included studies according to the Oxford Center for Evidence-Based Medicine checklist for randomized controlled trials (RCTs) and New Castle Othawa Quality Assessment Scale.[17]
Table 1

The characteristics of the included studies

Table 2

Quality assessment of the included studies according to Oxford Center for Evidence Based Medicine checklist for RCTs

Table 3

Quality assessment of nonrandomized studies according to NewCastle-Ottawa Quality Assessment Scale

The characteristics of the included studies Quality assessment of the included studies according to Oxford Center for Evidence Based Medicine checklist for RCTs Quality assessment of nonrandomized studies according to NewCastle-Ottawa Quality Assessment Scale

Qualitative synthesis

Generalized anxiety disorders

Three studies were conducted on GAD patients. Wells et al. compared MCT and applied relaxation (AR) in an RCT. Results showed that at posttreatment and at follow-up MCT was superior to AR.[13] van der Heiden et al. compared the effectiveness of MCT and intolerance-of-uncertainty therapy (IUT). These patients were randomly assigned to MCT, IUT, or delayed treatment (DT). With large ES (ranging between 0.94 and 2.39) both MCT and IUT, but not DT, produced significant reductions in GAD symptoms. They also showed that MCT provided better results than IUT.[18] Atash et al. in their study investigated the effectiveness of MCT on anxiety and metacognitive components in GAD patients. Results showed that patients in MCT group in all measures gained better results than the control group.[19]

Obsessive-compulsive disorder

Five studies evaluated the efficacy of MCT in the OCD patients. Sharreh et al. investigate the efficacy of MCT compare to fluvoxamine and the combination of MCT with fluvoxamine. Their results showed that unlike the fluvoxamine, the MCT and combined treatment led to significant improvements in Metacognitions Questionnaire (MCQ) components and subjective units of distress scale. However, there were no significant differences between MCT and combined therapy.[20] Khorramdel et al. investigated the effect of MCT on thought fusion in OCD patients. The study experimental group showed statistically significant decreases in thought fusion general scores in posttest and follow-up, compared with the control group.[21] Abolghasemi et al. investigated the effect of MCT and drug therapy on metacognitive beliefs of OCD patients. Their results showed that MCT was more effective in reducing symptoms, and modifying dysfunctional metacognitive beliefs than drug therapy.[22] Akrami et al. compared MCT and CBT in the treatment of OCD patients. According to their results, both methods effectively decreased obsessive-compulsive symptoms, however, there was no significant difference between CBT and MCT.[23] Abdolahzadeh et al. compared MCT and drug therapy in an obsession in OCD patients. Their results showed that MCT was more effective than the drug in reducing the severity of obsessions and stress and dysfunctional metacognitive beliefs. On the other hand; for general function, drug therapy produced better results than MCT.[24] Andouz et al. investigated the efficacy of MCT on patients with obsession. Their results indicated that MCT was effective in reducing OCD symptoms and modifying dysfunctional metacognitive and thought-fusion beliefs.[25]

Posttraumatic stress disorder

Two of the included studies reported the MCT effect on PTSD patients. Bakhtavar et al. investigated the efficacy of MCT on reducing self-punishment behaviors in PTSD. Their results showed that MCT was effective in reaching this goal.[26] Wells and Colbear evaluated MCT in treating PTSD patients. Their results indicated that MCT in comparison with control condition led to reductions in PTSD symptoms, depression, and anxiety.[27]

Panic disorder

Only Afshari et al. investigated MCT on panic beliefs in females suffering from panic disorder. They showed that MCT was effective in reducing panic beliefs compared to the control group.[28]

Social phobia

Bahadori et al. in three nonduplicate studies investigated the effectiveness of MCT on symptoms of social phobia fear of negative judgments, metacognitive beliefs, and cognitive confidence in patients suffering from social phobia.[102930] Their results showed that MCT had a significant effect in reducing symptoms of social phobia, fear of negative judgments, metacognitive beliefs, and cognitive confidence.

Quantitative synthesis (meta-analyses)

Three studies had enough information for the quantitative synthesis of MCT effect on GAD.[131819] Figure 2 shows the forest plots of these analyses. Standardized differences in means of psychological test score changes were 7.94 (95% confidence interval: 2.2-13.67) (P = 0.007, Q = 10 [P = 0.01], I2 = 90%), 7.18 (2.2-12.15) (P = 0.005, Q = 9.2 [P = 0.002], I2 = 89%), 7.68 (0.94-14.43) (P = 0.025, Q = 11.5 [P = 0.0006], I2 = 91%) for Penn State Worry Questionnaire (PSWQ), Beck Depression Inventory (BDI), and Beck Anxiety Inventory tests of the posttreatment period. For 12 months posttreatment data the pooled ES were 0.979 (0.616-1.343) (P < 0.00001, Q = 21 [P = 0.00001], I2 = 95%), and 0.633 (0.292-0.975) (P < 0.00001, Q = 5.8 [P = 0.01], I2 = 82%) for PSWQ and BDI, respectively.
Figure 2

(a) Forrest plot of the difference in means of changes in Beck Depression Inventory, Beck Anxiety Inventory, and Penn State Worry Questionnaire after metacognitive therapy in generalized anxiety disorders. (b) Forrest plot of difference in means of changes in Beck Depression Inventory, Beck Anxiety Inventory, and Penn State Worry Questionnaire after metacognitive therapy in generalized anxiety disorders for 12-month posttreatment

(a) Forrest plot of the difference in means of changes in Beck Depression Inventory, Beck Anxiety Inventory, and Penn State Worry Questionnaire after metacognitive therapy in generalized anxiety disorders. (b) Forrest plot of difference in means of changes in Beck Depression Inventory, Beck Anxiety Inventory, and Penn State Worry Questionnaire after metacognitive therapy in generalized anxiety disorders for 12-month posttreatment Three studies had enough information for quantitative synthesis of the MCT effect on OCD.[202223] Figure 3 shows the forest plot of the analyses. Standardized differences in means of psychological test score changes were 5.426 (4.272-6.581) (P < 0.00001, Q = 0.5 [P = 0.8], I2 = 0), and 1.835 (1.209-2.46) (P < 0.00001, Q = 25 [P = 0.000001], I2 = 95%) for MCQ global and Maudsley tests, respectively.
Figure 3

Forrest plot of the difference in means of changes in Metacognitions Questionnaire and Maudsley after metacognitive therapy in Obsessive-Compulsive Disorder

Forrest plot of the difference in means of changes in Metacognitions Questionnaire and Maudsley after metacognitive therapy in Obsessive-Compulsive Disorder Finally, two studies had enough information for the quantitative synthesis of the MCT effect on PTSD.[2627] Figure 4 shows the forest plot of the analysis. Standardized differences in means of psychological test score changes were 1.099 (0.504-1.694) (P < 0.00001, Q = 0.16 [P = 0.68], I2 = 0%) for Thought Control Questionnaire test.
Figure 4

Forrest plot of the difference in means of changes in Thought Control Questionnaire after metacognitive therapy in posttraumatic stress disorder

Forrest plot of the difference in means of changes in Thought Control Questionnaire after metacognitive therapy in posttraumatic stress disorder

DISCUSSION

In this study, we reviewed the available published clinical trials of MCT in adults with anxiety disorders. Our results showed that MCT had statistically significant effect on different domains in anxiety disorders. We located clinical trials on different anxiety disorders including GAD, OCD, PTSD, specific and social phobia, and panic disorder. All included studies showed better treatment results in the MCT arms compared to the control groups. We also statistically pooled the results across studies (when possible). The meta-analyses also showed that MCT had statistically significant better results compared to the control groups in GAD (both immediately posttreatment and 12 months posttherapy results), OCD, and PTSD (P values ranged <0.0001-0.025). Considering the aim of MCT that is gaining more control over the stream of thoughts particularly in anxiety provoking situations, and the nature of anxiety disorders (damage of natural information processing), it seems that MCT can be effective via modification of maladaptive metacognitive beliefs and facilitation of information processing. MCT gives the opportunity to patients to confront effectively with their beliefs about their disorders. In addition, the recovery rates and magnitude of change in MCT demonstrate that this therapy can be a highly effective treatment. The results of our systematic review also provide additional support for the relevance of Wells metacognitive model to the treatment and understanding of anxiety disorders.[102122] Thus far, several other systematic reviews have been published on psychotherapy for anxiety disorders in children and adolescents. For example, Watson and Rees conducted a meta-analysis on randomized, controlled treatment trials of pediatric OCD. Random effects modeling yielded statistically significant pooled ES estimates for pharmacotherapy (ES = 0.48, P < 0.00001) and cognitive-behavior therapy (ES = 1.45, P = 0.002). CBT showed a greater ES than pharmacotherapy.[31] In another study, Reynolds et al. conducted a meta-analytic review on psychotherapy for anxiety in children and adolescents. Psychological therapy for anxiety in children and adolescents was moderately effective overall, but ES were small to medium when psychological therapy was compared to an active control condition. The ES for non-CBT interventions was not statistically significant.[32] There are also several meta-analyses that investigated the effectiveness of CBT for anxiety disorders. For example, Butler et al. review 16 meta-analyses of CBT for different disorders. This review suggested that CBT is highly effective for adult unipolar depression, adolescent unipolar depression, GAD, panic disorder with or without agoraphobia, social phobia, PTSD, and childhood depressive and anxiety disorders. The comparison-weighted grand mean ES for these disorders, when compared to no-treatment, waitlist, or placebo controls, was 0.95 (standard deviation [SD] = 0.08). Statistically significant evidence for long-term effectiveness was also found for depression, generalized anxiety, panic, social phobia, OCD, sexual offending, schizophrenia, and childhood internalizing disorders.[33] Aside these studies that conducted meta-analyses on CBT and psychotherapy for anxiety disorders, we could not find any systematic review on MCT for anxiety disorders.

Limitations

Our systematic review had several limitations that should be taken into account while interpreting the results. First of all, the number of studies was limited which forced us to include both randomized and non-RCTs. This can limit the validity of our systematic review although only four of the included studies were nonrandomized. Our results were further limited by the quality of the included studies as most studies did not report the loss to follow-up and did not report on the intention to treat basis. We cannot use double-blind design for our study because, psychological therapy needs to be delivered by therapists who are not blind to the treatment, and this is a limitation. Another important limitation is the heterogeneity and quality of reporting in the included studies. The psychological tests used for evaluation of treatment effect varies considerably across the studies and limited the extraction of useful data. In addition, almost all of the included studies reported the averages and SDs of pre- and post-psychological tests in the treatment and control arms and in fact differences in pre- and post-treatment data were not compared between the MCT and control groups.

CONCLUSION

Based on the results of our systematic review, MCT seems to be an effective treatment for anxiety disorders and can effectively control their psychological problems. However, due to low number of the included studies and poor quality of their reporting, our results should be interpreted with caution. Further large studies with consistent design and better quality of report are needed in order to validate the results of our review.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

AUTHOR'S CONTRIBUTION

RS: analysis of the results, manuscript revision, writing of discussion. NM: writing of discussion, method, manuscript revision. LZM: analysis of the results. NA: (corresponding author), articles search, preparing the tables, writing of introduction, and manuscript revision. HS: preparing the tables.
  18 in total

1.  Meta-analysis in clinical trials.

Authors:  R DerSimonian; N Laird
Journal:  Control Clin Trials       Date:  1986-09

2.  Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication.

Authors:  Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Kathleen R Merikangas; Ellen E Walters
Journal:  Arch Gen Psychiatry       Date:  2005-06

Review 3.  Modelling cognition in emotional disorder: the S-REF model.

Authors:  A Wells; G Matthews
Journal:  Behav Res Ther       Date:  1996 Nov-Dec

4.  Metacognitive therapy for PTSD: a preliminary investigation of a new brief treatment.

Authors:  Adrian Wells; Sundeep Sembi
Journal:  J Behav Ther Exp Psychiatry       Date:  2004-12

5.  Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection.

Authors:  Kurt Kroenke; Robert L Spitzer; Janet B W Williams; Patrick O Monahan; Bernd Löwe
Journal:  Ann Intern Med       Date:  2007-03-06       Impact factor: 25.391

6.  An open trial of group metacognitive therapy for obsessive-compulsive disorder.

Authors:  Clare S Rees; Kate E van Koesveld
Journal:  J Behav Ther Exp Psychiatry       Date:  2008-01-18

7.  Meta-analysis of randomized, controlled treatment trials for pediatric obsessive-compulsive disorder.

Authors:  Hunna J Watson; Clare S Rees
Journal:  J Child Psychol Psychiatry       Date:  2008-05       Impact factor: 8.982

8.  A pilot randomized trial of metacognitive therapy vs applied relaxation in the treatment of adults with generalized anxiety disorder.

Authors:  Adrian Wells; Mary Welford; Paul King; Costas Papageorgiou; Julie Wisely; Elizabeth Mendel
Journal:  Behav Res Ther       Date:  2010-01-04

Review 9.  The epidemiology of anxiety disorders: prevalence and societal costs.

Authors:  Jean-Pierre Lépine
Journal:  J Clin Psychiatry       Date:  2002       Impact factor: 4.384

10.  Metacognitive therapy for obsessive-compulsive disorder: a case series.

Authors:  Peter L Fisher; Adrian Wells
Journal:  J Behav Ther Exp Psychiatry       Date:  2007-03-07
View more
  5 in total

1.  Inappropriate Metacognitive Status Increases State Anxiety in Genetic Counseling Clients.

Authors:  Yuka Shibata; Masaaki Matsushima; Megumi Takeuchi; Momoko Kato; Ichiro Yabe
Journal:  Front Psychol       Date:  2022-05-12

Review 2.  The Scope of Metacognitive Therapy in the Treatment of Psychiatric Disorders.

Authors:  Vandita Sharma; Rajesh Sagar; Gaurishanker Kaloiya; Manju Mehta
Journal:  Cureus       Date:  2022-03-23

3.  Impact of dissociation on treatment of depressive and anxiety spectrum disorders with and without personality disorders.

Authors:  Jan Prasko; Ales Grambal; Petra Kasalova; Dana Kamardova; Marie Ociskova; Michaela Holubova; Kristyna Vrbova; Zuzana Sigmundova; Klara Latalova; Milos Slepecky; Marta Zatkova
Journal:  Neuropsychiatr Dis Treat       Date:  2016-10-17       Impact factor: 2.570

4.  Neurobiological Mechanisms of Metacognitive Therapy - An Experimental Paradigm.

Authors:  Lotta Winter; Mesbah Alam; Hans E Heissler; Assel Saryyeva; Denny Milakara; Xingxing Jin; Ivo Heitland; Kerstin Schwabe; Joachim K Krauss; Kai G Kahl
Journal:  Front Psychol       Date:  2019-04-04

5.  Metacognitive Beliefs and Suicidal Ideation: An Experience Sampling Study.

Authors:  Vikki Aadahl; Adrian Wells; Robert Hallard; Daniel Pratt
Journal:  Int J Environ Res Public Health       Date:  2021-11-24       Impact factor: 3.390

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.